Sangamo Historical Financial Ratios
| SGMO Stock | USD 2.39 0.08 3.24% |
Sangamo Therapeutics is promptly reporting on over 107 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 0.45, Invested Capital of 0.0, Average Payables of 0.0 or Stock Based Compensation To Revenue of 0.15 will help investors to properly organize and evaluate Sangamo Therapeutics financial condition quickly.
Sangamo |
About Sangamo Financial Ratios Analysis
Sangamo TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Sangamo Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Sangamo financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Sangamo Therapeutics history.
Sangamo Therapeutics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Sangamo Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Sangamo Therapeutics sales, a figure that is much harder to manipulate than other Sangamo Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Sangamo Therapeutics dividend as a percentage of Sangamo Therapeutics stock price. Sangamo Therapeutics dividend yield is a measure of Sangamo Therapeutics stock productivity, which can be interpreted as interest rate earned on an Sangamo Therapeutics investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Free Cash Flow Yield
A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.Most ratios from Sangamo Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Sangamo Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.At this time, Sangamo Therapeutics' Capex Per Share is very stable compared to the past year.
| 2021 | 2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 20.98 | 14.67 | 2.75 | 2.61 | PTB Ratio | 2.89 | 1.64 | 1.14 | 1.09 |
Sangamo Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Sangamo Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Sangamo Therapeutics fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 9.16 | 17.75 | 9.79 | 4.35 | 0.54 | 0.51 | |
| Ptb Ratio | 2.17 | 4.22 | 2.89 | 1.64 | 1.14 | 1.09 | |
| Days Sales Outstanding | 133.95 | 19.33 | 20.98 | 14.67 | 2.75 | 2.61 | |
| Book Value Per Share | 3.86 | 3.7 | 2.6 | 1.91 | 0.48 | 0.45 | |
| Operating Cash Flow Per Share | 0.38 | (1.29) | 1.26 | (1.61) | (1.45) | (1.22) | |
| Stock Based Compensation To Revenue | 0.17 | 0.19 | 0.22 | 0.28 | 0.16 | 0.15 | |
| Pb Ratio | 2.17 | 4.22 | 2.89 | 1.64 | 1.14 | 1.09 | |
| Ev To Sales | 8.81 | 17.0 | 8.61 | 3.84 | 0.5 | 0.47 | |
| Free Cash Flow Per Share | (1.47) | 1.15 | (1.77) | (1.58) | (1.41) | (1.34) | |
| Roic | (0.19) | (0.26) | (0.49) | (0.68) | (3.24) | (3.08) | |
| Inventory Turnover | (306.31) | (6.48) | (3.58) | (0.11) | (0.12) | (0.13) | |
| Net Income Per Share | (0.68) | (0.9) | (1.23) | (1.25) | (1.48) | (1.55) | |
| Days Of Inventory On Hand | (56.32) | (102.1) | (3.4K) | 3.0E-5 | 3.5E-5 | 3.6E-5 | |
| Payables Turnover | 21.87 | 14.39 | 0.97 | 0.54 | 14.52 | 13.79 | |
| Capex To Revenue | 0.51 | 0.2 | 0.12 | 0.21 | 0.18 | 0.096 | |
| Cash Per Share | 3.23 | 4.77 | 2.6 | 1.8 | 0.46 | 0.44 | |
| Pocfratio | (6.5) | 12.35 | (4.65) | (2.17) | (0.42) | (0.44) | |
| Capex To Operating Cash Flow | (0.14) | 0.0866 | (0.0998) | (0.0902) | (0.0941) | (0.0894) | |
| Pfcf Ratio | (5.68) | 13.52 | (4.23) | (1.99) | (0.39) | (0.4) | |
| Days Payables Outstanding | 16.69 | 25.36 | 377.37 | 675.8 | 25.14 | 23.88 | |
| Income Quality | (0.54) | 1.51 | (1.4) | 1.31 | 1.16 | 0.87 | |
| Roe | (0.18) | (0.24) | (0.48) | (0.65) | (3.11) | (2.96) | |
| Ev To Operating Cash Flow | (6.25) | 11.83 | (4.09) | (1.91) | (0.39) | (0.41) | |
| Pe Ratio | (12.38) | (17.32) | (6.08) | (2.52) | (0.37) | (0.39) | |
| Ev To Free Cash Flow | (5.47) | 12.95 | (3.72) | (1.75) | (0.36) | (0.37) | |
| Earnings Yield | (0.0808) | (0.0577) | (0.16) | (0.4) | (2.72) | (2.58) | |
| Intangibles To Total Assets | 0.005528 | 0.16 | 0.14 | 0.11 | 0.13 | 0.0711 | |
| Net Debt To E B I T D A | 0.36 | 0.72 | 0.75 | 0.3 | 0.0812 | 0.0772 | |
| Current Ratio | 5.8 | 4.6 | 3.12 | 2.69 | 1.98 | 1.88 | |
| Tangible Book Value Per Share | 3.04 | 2.95 | 1.95 | 1.34 | 0.48 | 0.45 | |
| Receivables Turnover | 2.72 | 18.88 | 17.4 | 24.89 | 132.9 | 139.55 | |
| Graham Number | 7.66 | 8.66 | 8.49 | 7.32 | 3.98 | 4.25 | |
| Shareholders Equity Per Share | 3.86 | 3.7 | 2.6 | 1.91 | 0.48 | 0.45 | |
| Capex Per Share | 0.44 | 0.18 | 0.11 | 0.16 | 0.13 | 0.12 |
Pair Trading with Sangamo Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sangamo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sangamo Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Sangamo Stock
| 0.75 | ME | 23Andme Holding | PairCorr |
| 0.68 | VINC | Vincerx Pharma | PairCorr |
| 0.67 | VALN | Valneva SE ADR | PairCorr |
| 0.66 | DRMA | Dermata Therapeutics Buyout Trend | PairCorr |
| 0.65 | DOMH | Dominari Holdings | PairCorr |
The ability to find closely correlated positions to Sangamo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sangamo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sangamo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sangamo Therapeutics to buy it.
The correlation of Sangamo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sangamo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sangamo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sangamo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.24) | Revenue Per Share 0.066 | Quarterly Revenue Growth (0.95) | Return On Assets (0.58) | Return On Equity (1.94) |
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.